TW200616644A - Medicine for prevention or treatment of diabetes - Google Patents

Medicine for prevention or treatment of diabetes

Info

Publication number
TW200616644A
TW200616644A TW094125157A TW94125157A TW200616644A TW 200616644 A TW200616644 A TW 200616644A TW 094125157 A TW094125157 A TW 094125157A TW 94125157 A TW94125157 A TW 94125157A TW 200616644 A TW200616644 A TW 200616644A
Authority
TW
Taiwan
Prior art keywords
diabetes
medicine
prevention
treatment
chlorophenyl
Prior art date
Application number
TW094125157A
Other languages
English (en)
Inventor
Keisuke Inoue
Tarou Tamaki
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of TW200616644A publication Critical patent/TW200616644A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW094125157A 2004-07-27 2005-07-25 Medicine for prevention or treatment of diabetes TW200616644A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59150504P 2004-07-27 2004-07-27

Publications (1)

Publication Number Publication Date
TW200616644A true TW200616644A (en) 2006-06-01

Family

ID=35786147

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094125157A TW200616644A (en) 2004-07-27 2005-07-25 Medicine for prevention or treatment of diabetes

Country Status (4)

Country Link
EP (1) EP1772149A1 (zh)
JP (1) JPWO2006011397A1 (zh)
TW (1) TW200616644A (zh)
WO (1) WO2006011397A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2180787T3 (da) 2007-08-01 2014-02-03 Univ Pittsburgh Nitrooliesyremodulering af type ii-diabetes
WO2009134383A2 (en) 2008-05-01 2009-11-05 Complexa Inc. Vinyl substituted fatty acids
WO2009155439A2 (en) 2008-06-19 2009-12-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
EP2459189A4 (en) 2009-07-31 2013-01-16 Univ Pittsburgh FATTY ACIDS AS ANTI-INFLAMMATORY ACTIVE SUBSTANCES
EP2483233A4 (en) 2009-10-02 2013-08-14 Complexa Inc HETEROATOMA CONTAINING SUBSTITUTED FATTY ACIDS
JP2013534930A (ja) * 2010-06-28 2013-09-09 コンプレクサ，インコーポレイテッド 糖尿病を治療するための多成分調剤
EP2744491B1 (en) 2011-08-19 2020-07-29 The University of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
ES2971969T3 (es) 2015-07-07 2024-06-10 H Lundbeck As Inhibidores de PDE9 con cadena principal de imidazopirazinona para el tratamiento de enfermedades periféricas
KR20180098222A (ko) 2015-10-02 2018-09-03 컴플렉사, 인코포레이티드 활성화된 지방산의 치료학적 유효량을 이용한 질환의 예방, 치료 및 역행
CN117843645A (zh) 2018-05-25 2024-04-09 伊马拉公司 一种pde9抑制剂的一水合物和结晶形态

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4439947A1 (de) * 1994-11-09 1996-05-15 Boehringer Mannheim Gmbh 2,2-Dichloralkancarbonsäuren, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
ATE355840T1 (de) * 1997-06-18 2007-03-15 Smithkline Beecham Plc Behandlung der diabetes mit thiazolidindione und metformin
AR030920A1 (es) * 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
US7105556B2 (en) * 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
EP1452526A1 (en) * 2001-10-29 2004-09-01 Japan Tobacco Inc. Indole compound and medicinal use thereof
EP1473033A1 (en) * 2002-01-16 2004-11-03 Kowa Company Ltd. Medicinal composition containing 2,2-dichloro-12-(4-chlorophenyl)dodecanoic acid
KR100717098B1 (ko) * 2002-02-28 2007-05-10 니뽄 다바코 산교 가부시키가이샤 에스테르 화합물 및 그 의약 용도

Also Published As

Publication number Publication date
JPWO2006011397A1 (ja) 2008-05-01
EP1772149A1 (en) 2007-04-11
WO2006011397A1 (ja) 2006-02-02

Similar Documents

Publication Publication Date Title
TW200616644A (en) Medicine for prevention or treatment of diabetes
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2008021113A3 (en) Transdermal methods and systems for treating alzheimer's disease
AU2003256755A8 (en) Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
WO2004073614A3 (en) Combination therapy for the treatment of immunoinflammatory disorders
UA86344C2 (ru) Способ лечения сосудистых заболеваний
TW200738228A (en) Neramexane modified release matrix tablet
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
WO2004103297A3 (en) Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
CA2632207C (en) Use of calcitonin for the treatment of ra
NZ592615A (en) Method for treating or preventing thrombosis using 150 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
WO2011151722A3 (en) Methods and compositions for oral pharmaceutical therapy
EA200800075A1 (ru) Схема дозирования для празугреля
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
WO2006113718A3 (en) Compositions for the treatment of neoplasms
PL1656131T3 (pl) Zastosowanie betainy w leczeniu chromania przestankowego
GB2446341A (en) Method and system for transdermal drug delivery
NZ592613A (en) Method for treating or preventing thrombosis using >150 mg to 300 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
WO2004087880A3 (en) Compounds and their use to treat diabetes and related disorders
ATE447953T1 (de) Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis
TW200608965A (en) Medicine for prevention or treatment of diabetes